Exploring what matters most to patients in relapsed refractory multiple myeloma treatment: a Canadian discrete choice experiment with patients, caregivers and physicians
While participants showed no significant preference between the administration profiles of CAR-T therapy and conventional treatments, CAR-T therapy was favored for its clinical benefits of potentially increased survival and lower long-term side effect risks. These findings are valuable for Canadian patient-centered clinical and reimbursement decision-making, highlighting the potential role of CAR-T therapy in addressing patient needs.
Authors
- Arleigh McCurdy (ORCID: https://orcid.org/0000-0002-8809-4368)
- Kun Shi
- Richard K. Plante
- Bonnie Macfarlane (ORCID: https://orcid.org/0000-0002-8742-5292)
- Gin Nie Chua (ORCID: https://orcid.org/0000-0002-1602-3915)
- Martine Elias
- Scott Gerard Soltys (ORCID: https://orcid.org/0000-0002-5360-7063)
- Jill J. Ranger
- Rebekah Hall
Institutions
- Johnson & Johnson (United States) (US)
- Ottawa Hospital (CA)
- GLS Industries (Canada) (CA)
- Lloyd's (GB)
- Ottawa Hospital Research Institute (CA)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12885-025-14490-5
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00